Your browser doesn't support javascript.
loading
Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trial.
Duffley, Gordon; Szabo, Aniko; Lutz, Barbara J; Mahoney-Rafferty, Emily C; Hess, Christopher W; Ramirez-Zamora, Adolfo; Zeilman, Pamela; Foote, Kelly D; Chiu, Shannon; Pourfar, Michael H; Goas Cnp, Clarisse; Wood, Jennifer L; Haq, Ihtsham U; Siddiqui, Mustafa S; Afshari, Mitra; Heiry, Melissa; Choi, Jennifer; Volz, Monica; Ostrem, Jill L; San Luciano, Marta; Niemann, Nicki; Billnitzer, Andrew; Savitt, Daniel; Tarakad, Arjun; Jimenez-Shahed, Joohi; Aquino, Camila C; Okun, Michael S; Butson, Christopher R.
Afiliação
  • Duffley G; Scientific Computing and Imaging Institute, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.
  • Szabo A; Division of Biostatistics, Institute for Health & Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Lutz BJ; School of Nursing, University of North Carolina-Wilmington, Wilmington, NC, USA.
  • Mahoney-Rafferty EC; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Hess CW; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Ramirez-Zamora A; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Zeilman P; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Foote KD; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Chiu S; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Pourfar MH; Center for Neuromodulation, New York University Langone Medical Center, New York, NY, USA.
  • Goas Cnp C; Department of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Wood JL; Department of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Haq IU; Department of Neurology, University of Miami, Miami, FL, USA.
  • Siddiqui MS; Department of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Afshari M; Department of Neurological Sciences, Section of Movement Disorders, Rush University, Chicago, IL, USA.
  • Heiry M; Weill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Choi J; Weill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Volz M; Weill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Ostrem JL; Weill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • San Luciano M; Weill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Niemann N; Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Billnitzer A; Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Savitt D; Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Tarakad A; Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Jimenez-Shahed J; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Aquino CC; Department of Neurology, University of Utah, Salt Lake City, UT, USA; Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  • Okun MS; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
  • Butson CR; Scientific Computing and Imaging Institute, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology
Parkinsonism Relat Disord ; 109: 105346, 2023 04.
Article em En | MEDLINE | ID: mdl-36966051
ABSTRACT

INTRODUCTION:

Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD), but its efficacy is tied to DBS programming, which is often time consuming and burdensome for patients, caregivers, and clinicians. Our aim is to test whether the Mobile Application for PD DBS (MAP DBS), a clinical decision support system, can improve programming.

METHODS:

We conducted an open-label, 11 randomized, controlled, multicenter clinical trial comparing six months of SOC standard of care (SOC) to six months of MAP DBS-aided programming. We enrolled patients between 30 and 80 years old who received DBS to treat idiopathic PD at six expert centers across the United States. The primary outcome was time spent DBS programming and secondary outcomes measured changes in motor symptoms, caregiver strain and medication requirements.

RESULTS:

We found a significant reduction in initial visit time (SOC 43.8 ± 28.9 min n = 37, MAP DBS 27.4 ± 13.0 min n = 35, p = 0.001). We did not find a significant difference in total programming time between the groups over the 6-month study duration. MAP DBS-aided patients experienced a significantly larger reduction in UPDRS III on-medication scores (-7.0 ± 7.9) compared to SOC (-2.7 ± 6.9, p = 0.01) at six months.

CONCLUSION:

MAP DBS was well tolerated and improves key aspects of DBS programming time and clinical efficacy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Núcleo Subtalâmico / Estimulação Encefálica Profunda / Aplicativos Móveis Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Núcleo Subtalâmico / Estimulação Encefálica Profunda / Aplicativos Móveis Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article